Author/Authors :
Shi, Tingting the Hangzhou Xixi Hospital Affiliated to Zhejiang Medical University, Zhejiang, China , Yu, Liping College of Pharmaceutical Science - Yunnan University of Traditional Chinese Medicine - Yunnan, China , Zhuang, Rangxiao the Hangzhou Xixi Hospital Affiliated to Zhejiang Medical University, Zhejiang, China , Xi, Jianjun the Hangzhou Xixi Hospital Affiliated to Zhejiang Medical University, Zhejiang, China , He, Ruoyu the Hangzhou Xixi Hospital Affiliated to Zhejiang Medical University, Zhejiang, China , Shao, Yidan the Hangzhou Xixi Hospital Affiliated to Zhejiang Medical University, Zhejiang, China , Huang, Jinsong the Hangzhou Xixi Hospital Affiliated to Zhejiang Medical University, Zhejiang, China , Liu, Shourong the Hangzhou Xixi Hospital Affiliated to Zhejiang Medical University, Zhejiang, China , Yang, Xingxin College of Pharmaceutical Science - Yunnan University of Traditional Chinese Medicine - Yunnan, China
Abstract :
Metabolic associated fatty liver disease (MAFLD) is a multifactorial systemic disorder that occurs in the absence of excessive alcohol consumption. The disease is characterized by fatty degeneration and fat accumulation in liver parenchymal cells, the incidence of which is increasing annually, particularly in younger adults. MAFLD is caused by genetic and metabolism related disorders, of which mitochondrial dysfunction is the major contributor. Natural products can relieve MAFLD through restoring mitochondrial function. In this article, we describe the relationship between mitochondria and MAFLD and discuss the beneficial effects of natural products as a future anti-MAFLD strategy. Significance Statement. We herein propose that the development of mitochondrial regulators/nutrients from natural products can remedy mitochondrial dysfunction which represents an attractive strategy for the treatment of MAFLD. Furthermore, the mitochondrial regulation of natural products can provide new insight into the underlying mechanisms of action of natural products used for future MAFLD therapeutics.
